Controversies in Rabies Vaccination
Controversies in Rabies Vaccination
复制标题
狂犬病疫苗接种的争议
DOI：
10.1007/bf02723141
复制
发表时间：
2003
期刊：
影响因子：
--
通讯作者：
T. K. Ghosh
中科院分区：
文献类型：
--
作者：
T. K. Ghosh
狂犬病是百分之一的致命疾病，给受害者注射狂犬病疫苗不应该有任何争议。世卫组织对不同类别病例的暴露前和暴露后剂量都有固定的时间表，这也有助于我们避免所有争议。但争议主要集中在与狂犬病预防策略相关的五个方面。它们是： (i) 用 MTCV 取代 NTV。 (ii) MTCV 皮内注射方案，代替 5 次 IM 剂量的 Essen 方案，以降低成本。 (iii) 将暴露前剂量的 MTCV 作为额外疫苗纳入儿童免疫接种计划中的可接受性和纳入 (iv) 已暴露后接种疫苗病例的再次暴露时间表和暴露前疫苗接种病例的暴露时间表。 (v) RIG 在 WHO III 类病例中的使用。如果科学地考虑这些有争议的问题，狂犬病预防将会看到成功的曙光。
Rabies is a cent per cent fatal disease and there should not be any controversy in giving rabies vaccine to the victims. WHO has fixed schedules for doses for both pre and post–exposure in different category of cases, which also help us to avoid all controversies. But controversies arise in five main areas, which are related to the strategies of rabies prevention. These are : (i) Replacing use of NTV by MTCV. (ii) Intradermal schedule of MTCV, in place of Essen protocol of 5 IM doses to reduce the cost. (iii) Acceptability and inclusion of pre-exposure doses of MTCV in the immunization schedule of children as additional vaccine (iv) Schedule for re–exposure in already post-exposure vaccinated cases and schedule for exposure in pre-exposure vaccinated cases. (v) Uses of RIG in WHO category III cases. If these controversial issues are considered scientifically, rabies prophylaxis will see the light of success.